Global Antiemetic Drugs Market: Snapshot
Antiemetic drugs are prescribed to tackle nausea and vomiting, usually arising from intake of other drugs such as those administered for anesthesia to carry out surgeries or chemotherapy for cancer. Antiemetic drugs are usually taken orally. Sometimes they are injected and at other times administered by placing a patch on the body.
Majorly fuelling the demand for antiemetic drugs is a fast expanding geriatric population worldwide that is highly susceptible to diseases such as cancer which is mostly treated through chemotherapy – something that results in side effects such as vomiting. In addition, growing number of gastroenteritis patients are also serving to stoke demand.
The market for antiemetic drugs, which has clocked steady growth so far, will likely expand further but at a lackluster pace in the years to come on account of a drying clinical pipeline. The cost of research and development is steep and this is deterring development of new drugs. As a result, many savvy companies are carefully considering undertaking new molecule or drug research projects.
Large companies manufacturing drugs, however, are partnering with smaller biotechnology and research companies to come up with newer and more effective antiemetic drugs. The small biotech research companies lack the necessary means to conduct various late stage clinical trials that are usually capital intensive, but often have strong research and development capabilities. Hence, large firms obtain the rights of the drug by paying the small companies one-time. They also pay royalties on recurrent sales. It’s a win-win for both.
An antiemetic is a drug which is effectively used to prevent vomiting and nausea, side effects of opioid analgesics, etc. It is available as over-the-counter and prescribed drug at recommended doses. It is mostly used to prevent motion sickness rather than treating it. Presence of antihistamine and central anticholinergic properties make antiemetic drugs quite effective. The drug is as effective as cetirizine, a non-sedating antihistamine, does not cross the blood-brain barrier, and is not effective in either preventing or treating motion sickness. Nausea and vomiting is identified as the primary symptoms and in sometimes it can leads to other complications such as erosion of the tooth dehydration, and loss of appetite. These can affect daily activities and the quality of life if left untreated. Antiemetic drugs work by suppressing the vomiting reflex in the body. Motility stimulants work by increasing the movement through the gastrointestinal tract and serotonin antagonists suppress the signals to and from the vomiting center of the brain. Various types of antiemetic drugs are available with a number of medical applications. Antiemetic drugs can be administered orally, intramuscularly, or as a suppository.
Based on drug class, the antiemetic drugs market has been segmented into 5-HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonists, H1 receptor antagonists, cannabinoids, benzodiazepines, anticholinergics, and steroids. In terms of application, the market has been categorized into dizziness, motion sickness, and others. The rapid rise of geriatric population is diagnosed with different types of disease like cancer where chemotherapy is a standard treatment and it poses side effect such as vomiting. Moreover, increasing number of gastroenteritis patients drives the antiemetic drugs market. However, the clinical pipeline for antiemetic drugs is dry and has been identified as one of the major factors likely to restrain the global antiemetic drugs market. Presently, rising cost in various research and development processes is exerting a lot of pressure on various drug making companies. Productivity in the antiemetic drugs market has also declined significantly in the past few years. This has induced companies to rethink before undertaking any new molecule or drug research projects. Hence, large drug manufacturing companies have started collaborating with various small biotechnology and research companies. These small biotech research companies do not have sufficient capital to carry out various late stage clinical trials that incur high capital expenditures, but have strong R&D capabilities. Therefore, large firms obtain the rights of the drug through one-time payment to these small companies and some royalties are paid on recurrent sales. For instance, in July 2011, Trius Therapeutics, Inc. entered into a partnership with Bayer AG for the development and commercialization of its antibacterial drug Tedizolid phosphate (in phase III clinical trials). In July 2013, Cubist Pharmaceuticals acquired Trius Therapeutics. Hence, Cubist and Bayer are now in the late stage clinical trials of the drug which will treat some gram positive infections including MRSA.
In terms of region, North America dominates the global antiemetic drugs market. This is attributed to well-established health care infrastructure, technological advancements, and favorable government support in the region. Europe holds the second position in the global antiemetic drugs market. Rapid rise in geriatric population and growing number of cancer patients are boosting market growth in the region. The market in Asia Pacific is projected to grow at the highest rate owing to rapid rise of health care infrastructure, rising disposable income of people, improving economic conditions, and increasing purchasing power of people.
GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson, Sanofi, Merck & Co., Novartis AG, Bristol-Myers Squibb, Astellas Pharma, Inc., Eli Lilly and Company, Abbott, Cipla Ltd., Dr. Reddy’s Laboratories Ltd, Baxter International, and IPCA Labs are the major players operating in the global antiemetic drugs market.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.